Edwards Lifesciences Corporation (EW) CEO Michael A. Mussallem Sells 32,900 Shares

Edwards Lifesciences Corporation (NYSE:EW) CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $112.45, for a total value of $3,699,605.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Michael A. Mussallem also recently made the following trade(s):

  • On Wednesday, August 9th, Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock. The shares were sold at an average price of $115.99, for a total value of $3,816,071.00.
  • On Monday, July 31st, Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock. The shares were sold at an average price of $114.80, for a total value of $3,776,920.00.

Shares of Edwards Lifesciences Corporation (NYSE:EW) opened at 115.13 on Tuesday. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75. The firm has a 50-day moving average price of $114.35 and a 200 day moving average price of $108.51. The stock has a market cap of $24.31 billion, a price-to-earnings ratio of 34.92 and a beta of 0.64.

Edwards Lifesciences Corporation (NYSE:EW) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business had revenue of $842 million for the quarter, compared to the consensus estimate of $839.16 million. During the same quarter in the previous year, the company posted $0.76 EPS. The company’s revenue was up 10.9% compared to the same quarter last year. On average, analysts forecast that Edwards Lifesciences Corporation will post $3.78 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2017/09/12/edwards-lifesciences-corporation-ew-ceo-michael-a-mussallem-sells-32900-shares.html.

Large investors have recently added to or reduced their stakes in the business. YorkBridge Wealth Partners LLC bought a new stake in Edwards Lifesciences Corporation in the 1st quarter worth approximately $110,000. ETF Managers Group LLC bought a new stake in Edwards Lifesciences Corporation in the 2nd quarter worth approximately $112,000. NEXT Financial Group Inc increased its stake in Edwards Lifesciences Corporation by 91.7% in the 1st quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock worth $115,000 after acquiring an additional 500 shares during the last quarter. Shine Investment Advisory Services Inc. bought a new stake in Edwards Lifesciences Corporation in the 2nd quarter worth approximately $126,000. Finally, Cornerstone Advisors Inc. increased its stake in Edwards Lifesciences Corporation by 25.1% in the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock worth $129,000 after acquiring an additional 219 shares during the last quarter. 82.36% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts have recently weighed in on EW shares. Stifel Nicolaus reiterated a “buy” rating and set a $130.00 price target (up from $118.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Royal Bank Of Canada reiterated a “buy” rating and set a $130.00 price target on shares of Edwards Lifesciences Corporation in a research report on Friday, July 28th. Zacks Investment Research upgraded Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price target on the stock in a research report on Tuesday, July 18th. SunTrust Banks, Inc. upped their price target on Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a research report on Monday, July 17th. Finally, Jefferies Group LLC upped their price target on Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the company a “buy” rating in a research report on Thursday, July 27th. Six investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $120.75.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply